Synthesis and therapeutic evaluation of an aptide–docetaxel conjugate targeting tumor-associated fibronectin

Kim, Hyungjun; Lee, Yonghyun; Lee, In Hyun; Kim, Sung-Hyun; Kim, Daejin; Saw, Phei Er; Lee, Jinju; Choi, Minsuk; Kim, Yong Chul; Jon, Sangyong

doi:10.1016/j.jconrel.2014.01.015

Cited by 40 publications

(21 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FoxC2 may regulate tumor vasculature, growth, invasion, and metastasis [23]. We examined β-catenin, which is an epithelial marker, Vimentin, which is a mesenchymal marker, and Fibronectin, which highly correlates with cancer metastasis [24,25]. We also assessed E-cadherin, which is one of the major EMT-related proteins.…”

Section: Discussionmentioning

confidence: 99%

STK33 plays an important positive role in the development of human large cell lung cancers with variable metastatic potential

Wang¹,

Cheng²,

Wu³

et al. 2015

ABBS

View full text Add to dashboard Cite

Serine/threonine kinase 33 (STK33) is a novel protein that has attracted considerable interest in recent years. Previous research has revealed that STK33 expression plays a special role in cancer cell proliferation. However, the mechanisms of STK33 induction of cancer cells remain largely unknown. In this study, it is demonstrated that STK33 expression varies in NL9980 and L9981 cells which are homogeneous cell lines with similar genetic backgrounds. STK33 can promote cell migration and invasion and suppress p53 gene expression in the NL9980 and L9981 cells. In addition, this protein also promotes epithelial-mesenchymal transition (EMT). Moreover, STK33 knockdown decreases tumor-related gene expression and inhibits cell migration, invasion, and EMT, suggesting that STK33 may be a mediator of signaling pathways that are involved in cancer. In conclusion, our results suggest that STK33 may be an important prognostic marker and a therapeutic target for the metastatic progression of human lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

STK33 plays an important positive role in the development of human large cell lung cancers with variable metastatic potential

Wang¹,

Cheng²,

Wu³

et al. 2015

ABBS

View full text Add to dashboard Cite

show abstract

“…The EDB targeting nanoparticles loaded with PTX resulted in enhanced tumor regression and a prolonged survival as compared to the free drug. Direct conjugation of APT EDB to docetaxel (DTX) also yielded an improved delivery efficiency of docetaxel in glioma, with enhanced therapeutic effects 105 . In another study, ZD2 was conjugated to DOX, yielding an amphiphilic compound that self-assembles into nanoparticles 102 .…”

Section: Targeting Fibronectin In Cancer Therapymentioning

confidence: 99%

Targeting fibronectin for cancer imaging and therapy

2017

View full text Add to dashboard Cite

During cancer progression, the extracellular matrix (ECM) undergoes dramatic changes, which promote cancer cell migration and invasion. In the remodeled tumor ECM, fibronectin (FN) level is upregulated to assist tumor growth, progression, and invasion. FN serves as a central organizer of ECM molecules and mediates the crosstalk between the tumor microenvironment and cancer cells. Its upregulation is correlated with angiogenesis, cancer progression, metastasis, and drug resistance. A number of FN-targeting ligands have been developed for cancer imaging and therapy. Thus far, FN-targeting imaging agents have been tested for nuclear imaging, MRI, and fluorescence imaging, for tumor detection and localization. FN-targeting therapeutics, including nuclear medicine, chemotherapy drugs, cytokines, and photothermal moieties, were also developed in cancer therapy. Because of the prevalence of FN overexpression in cancer, FN targeting imaging agents and therapeutics have the promise of broad applications in the diagnosis, treatment, and image-guided interventions of many types of cancers. This review will summarize current understanding on the role of FN in cancer, discuss the design and development of FN-targeting agents, and highlight the applications of these FN-targeting agents in cancer imaging and therapy.

show abstract

“…This conjugate is in clinical trials for the treatment of advanced solid tumors in patients with brain metastases. 148 A number of cancer-targeting PDCs, such as camptothecin-somatostatin conjugate, 149 camptothecin-bombesin conjugate, 150,151 H2009.1 peptide-polyglutamic aciddoxorubicin conjugate, 152 cyclic RGD peptide-paclitaxel conjugate, 153 RGD-4C peptide-doxorubicin conjugate,- 154,155 aptide-SN38 conjugate, 156 and aptide-docetaxel conjugate, 157 have been developed and are being explored in targeted cancer therapy. Tai et al prepared a PDC consisting of HER2-specific peptide conjugated to TGX-221, a potent inhibitor of PI3Kβ, a lipid enzyme that has been found to be over-activated in human cancers, such as prostate cancer.…”

Section: Lectinsmentioning

confidence: 99%

<p>Smart Targeting To Improve Cancer Therapeutics</p>

Morales‐Cruz¹,

Delgado²,

Castillo³

et al. 2019

DDDT

103

101

View full text Add to dashboard Cite

Cancer is the second largest cause of death worldwide with the number of new cancer cases predicted to grow significantly in the next decades. Biotechnology and medicine can and should work hand-in-hand to improve cancer diagnosis and treatment efficacy. However, success has been frequently limited, in particular when treating late-stage solid tumors. There still is the need to develop smart and synergistic therapeutic approaches to achieve the synthesis of strong and effective drugs and delivery systems. Much interest has been paid to the development of smart drug delivery systems (drug-loaded particles) that utilize passive targeting, active targeting, and/or stimulus responsiveness strategies. This review will summarize some main ideas about the effect of each strategy and how the combination of some or all of them has shown to be effective. After a brief introduction of current cancer therapies and their limitations, we describe the biological barriers that nanoparticles need to overcome, followed by presenting different types of drug delivery systems to improve drug accumulation in tumors. Then, we describe cancer cell membrane targets that increase cellular drug uptake through active targeting mechanisms. Stimulusresponsive targeting is also discussed by looking at the intra-and extracellular conditions for specific drug release. We include a significant amount of information summarized in tables and figures on nanoparticle-based therapeutics, PEGylated drugs, different ligands for the design of active-targeted systems, and targeting of different organs. We also discuss some still prevailing fundamental limitations of these approaches, eg, by occlusion of targeting ligands.

show abstract

Synthesis and therapeutic evaluation of an aptide–docetaxel conjugate targeting tumor-associated fibronectin

Cited by 40 publications

References 36 publications

STK33 plays an important positive role in the development of human large cell lung cancers with variable metastatic potential

STK33 plays an important positive role in the development of human large cell lung cancers with variable metastatic potential

Targeting fibronectin for cancer imaging and therapy

<p>Smart Targeting To Improve Cancer Therapeutics</p>

Contact Info

Product

Resources

About